Franklin Strategic Biotechnology: (MF: FBDIX)
NAV
$108.71
NAV Day Change
-2.07 (-1.87%)
May 16 06:05 PM ET
General Information As Of 04/30/13
| %Yield | 0.06 |
| %SEC Yield | NA |
| %YTD Return (as of 04/30/13) | 27.37 |
| Objective* | Equity - Sector Health |
| Peer* | HL MG |
Portfolio Statistics
| %Unrealized Gain YTD | 23.75 |
| Net Assets (Mil $) 04/30/2013 | 469.29 |
| %Turnover 04/30/2013 | 46.54 |
Fees
| %Max Sales Load | 5.75 |
| %Min Sales Load | .00 |
| %Max Deferred Load | NA |
Expenses
| %Max 12b-1 Fee | 0.29 |
| %Max Management Fee | 0.52 |
| Redemption Fee | NA |
| Expense Ratio | 1.16 |
Allocation
| Large Growth | 57.80 |
| Large Value | 0.00 |
| Small Growth | 0.00 |
| Small Value | 0.00 |
| Foreign Stock | 0.00 |
| Emerging Market | 0.00 |
| Precious Metal | 0.00 |
| Intermediate Bond | 0.00 |
| Foreign Bond | 0.00 |
| High Yield Bond | 0.00 |
Portfolio Information
Composition
| As of 01/31/2013 | %of Net Assets |
| Stock | 93.02 |
| Cash | 13.03 |
| Bonds | 0.00 |
| Preferred | 0.92 |
| Convertibles | 0.00 |
| Foreign Stock | 5.45 |
| Foreign Bonds | 0.00 |
| Hedge | 0.00 |
| Other | -6.98 |
Sector / Country Weightings
| As of 04/30/2013 | % of Portfolio |
|---|---|
| Health | 57.36 |
| Services | 19.60 |
| Other | 9.59 |
| Industrial Cyclical | 9.46 |
| Retail Trade | 1.87 |
| Technology | 1.71 |
| Non-Durable | 0.41 |
Portfolio Holdings
| Top Equity Holdings (As of 10/31/2012) | % of Portfolio | Value (Mil$) |
|---|---|---|
| GILEAD SCIENCES INC | 9.37 | 45.30 |
| CELGENE CORP | 7.22 | 34.91 |
| BIOGEN IDEC INC | 6.94 | 33.54 |
| AMGEN INC | 6.54 | 31.61 |
| ONYX PHARMACEUTICALS INC | 4.69 | 22.68 |
| ALEXION PHARMACEUTICALS I | 4.32 | 20.87 |
| VERTEX PHARMACEUTICALS IN | 3.80 | 18.39 |
| ARIAD PHARMACEUTICALS INC | 2.92 | 14.14 |
| MEDIVATION INC | 2.77 | 13.38 |
Contact Information
| Family | Franklin/Temp |
| Addrerss | One Franklin Pkwy San Mateo, CA 94403 |
| Phone | 800 632-2301 |
Zacks Premium Research
Zacks Mutual Fund Rank: 1 - Strong Buy 
| #1 |
Fund Description
The fund was incepted in September 1997 and is managed by Franklin Advisers. The objective of this fund is to seek capital appreciation. The fund invests at least 80% of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy and other select medical companies. The fund invests a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with a market capitalization of less than $1.5 billion at the time of the fund's investment, and invests a small portion of its assets in private or illiquid securities, such as late stage venture capital financings. The fund offers dividends and capital gains annually. There is no guarantee that fund would regularly pay either income dividends or capital gains distributions.
Stock Holding % of Net Assets
| As Of | 01/31/2013 |
| Total Issues | 62 |
| Avg. P/E | 44.50 |
| Avg. P/Book | 6.29 |
| Avg. EPS Growth | 15.11 |
| Avg. Market Value (Mil $) | 19,545 |
Risk
| 3 Year | 5 Year | 10 Year | |
|---|---|---|---|
| Beta | 1.03 | 0.72 | 0.80 |
| Alpha | 9.81 | 13.93 | 6.23 |
| R Squared | 0.67 | 0.48 | 0.42 |
| Std. Dev. | 18.93 | 19.60 | 18.14 |
| Sharpe | 1.34 | 0.99 | 3.00 |
Shareholder Information
| Manager | Evan McCulloch |
| Since | 09/97 |
| Manager Rating | 1.50 |
| Inception Date | 09/15/1997 |
| Shareholders | NA |
| Dividends Paid | A |
| Minimum Initial Investment | $1,000 |
| Minimum Subsequent Investment | $0 |
| IRA Minimum | $250 |
| IRA Available | Y | Check Writing | N | Phone Invest | Y |
| Phone Exchange | Y | Phone Redeem | Y | Auto Invest | Y |
| Wire Redeem | Y | Wire Fee | Y | Wire Transfer | Y |
Zacks Commentary for FBDIX
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Apr 09, 2013
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Nov 28, 2012
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Nov 23, 2012
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Oct 29, 2012
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Oct 17, 2012
